Company intelligence / Profile preview

Sequentify

Rehovot, Central District, Israelsequentify.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sequentify has developed the InfiniSeq™ platform for rapid, cost-effective targeted next-generation sequencing (NGS) library preparation. Their technology enables sample-to-sequencing in as little as 3.5 hours with a one-tube protocol and full automation support. The company’s products are used in clinical and research settings for applications such as cancer diagnostics, COVID surveillance, carrier screening, and large-scale population genomics studies.

Therapeutic areas: OtherOncologyRare DiseasesInfectious Diseases
Modalities: Diagnostic panel (NGS-based)Software/Analysis platform (for NGS data)
Industry: Molecular Diagnostics

Partnerships

Bio Molecular Systems (“InfiniSeq Myra Protocol” for automated NGS library prep)

Beyond the preview

Go deeper on Sequentify.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequentify.

Explore the full profile